Holen Sie sich die Stockscreener-App
11.90
1.19%
0.14
Handel nachbörslich:
11.90
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
Oric Pharmaceuticals (ORIC) Sees Opportunity Amid Market Dynamics - GuruFocus
Oric Pharmaceuticals' (ORIC) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
ORIC Pharmaceuticals Reiterates 'Buy' Rating with $25 Target by HC Wainwright | ORIC Stock News - GuruFocus
Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns - Yahoo Finance
ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Peer Drug Withdrawal Triggers Safety ScrutinyWhat's Changed - simplywall.st
JPMorgan reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
Oric Pharmaceuticals celebrates Employee Appreciation Day with recognition initiatives - Traders Union
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Up 8.8%Here's Why - MarketBeat
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained - AOL.com
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained - 24/7 Wall St.
Constructive Buy Thesis on ORIC Driven by Differentiated PRC2 Biology and Manageable Safety Profile for Rinzimetostat - TipRanks
March 2026 Cantor Fitzgerald Maintains Overweight on ORIC (ORIC) - Meyka
ORIC Stock Recovers Amid Potential for Long-Term Success Despite Temporary Setback - GuruFocus
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownWhat's Next? - MarketBeat
Technical Reactions to ORIC Trends in Macro Strategies - Stock Traders Daily
Oric Pharmaceuticals stock tumbles on Tazverik withdrawal By Investing.com - Investing.com Australia
Oric Pharmaceuticals stock tumbles on Tazverik withdrawal - Investing.com UK
Jones Trading reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
ORIC Pharmaceuticals Shares Drop Following Ipsen's Drug Withdrawal - GuruFocus
After Golden Cross, Oric Pharmaceuticals, Inc. (ORIC)'s Technical Outlook is Bright - Finviz
ORIC Pharmaceuticals: Differentiated PRC2 Inhibitor Rinzimetostat Mitigates Sector Safety Overhang and Supports Buy Rating - TipRanks
After the Golden Cross, the technical perspective for Oric Pharmaceuticals, Inc. (ORIC) appears promising - Bitget
Is ORIC Pharmaceuticals Inc. stock positioned for digital transformation2026 Drop Watch & Reliable Breakout Stock Forecasts - Naître et grandir
Trend Report: What is ORIC Pharmaceuticals Inc.’s market positionGap Down & Entry Point Confirmation Signals - baoquankhu1.vn
Oric Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Earnings Update And New Shelf Registration - simplywall.st
JPMorgan Chase & Co. Has $14.74 Million Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Is ORIC’s ESOP Shelf And Narrower Quarterly Loss Altering The Investment Case For ORIC (ORIC)? - simplywall.st
History Review: What is ORIC Pharmaceuticals Incs market position2025 Volatility Report & AI Enhanced Trading Alerts - baoquankhu1.vn
ORIC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Oric Pharmaceuticals, Inc. $ORIC Stake Raised by Royce & Associates LP - MarketBeat
Oric Pharmaceuticals Teases Key 2026 Catalysts, Phase 3 Plans for Prostate and Lung Cancer Drugs - MarketBeat
ORIC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Uncovering a 57% Upside Potential in Biotech - DirectorsTalk Interviews
ORIC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
ORIC Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Sell: Dominic Piscitelli Sells 52,000 Shares of ORIC Pha - GuruFocus
Dominic Piscitelli Sells 52,000 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat
Oric Pharmaceuticals Insider Sold Shares Worth $702,686, According to a Recent SEC Filing - marketscreener.com
Oric Pharmaceuticals CFO Dominic Piscitelli Sells 52,000 Shares - TradingView
ORIC (ORIC) CFO exercises options and sells 52,000 shares in 10b5-1 trades - Stock Titan
Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to Trade - Finviz
Trading the Move, Not the Narrative: (ORIC) Edition - Stock Traders Daily
Q1 EPS Forecast for Oric Pharmaceuticals Raised by Analyst - MarketBeat
Oppenheimer Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC) - The Globe and Mail
ORIC: Phase III prostate cancer trial and key data updates position both programs for potential market impact - TradingView
ORIC: Phase 3 and key data updates for two oncology programs aim to drive differentiation and growth - TradingView
Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright - Yahoo Finance
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Results And Extended Cash Runway - simplywall.st
H.C. Wainwright raises ORIC Pharmaceuticals price target on trial progress - Investing.com Australia
H.C. Wainwright Maintains Buy on ORIC (ORIC Pharmaceuticals, Inc.) Feb 2026 - Meyka
H.C. Wainwright raises ORIC Pharmaceuticals price target on trial progress By Investing.com - Investing.com Canada
Assessing ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Data And US$264 Million Capital Raise - Yahoo Finance
[144] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ORIC: Citigroup Raises Price Target to $17, Maintains Buy Rating - GuruFocus
ORIC: Citigroup Raises Price Target to $17, Maintains Buy Rating | ORIC Stock News - GuruFocus
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 7.9% Higher Following Earnings Beat - MarketBeat
ORIC Pharmaceuticals (ORIC) Sees Price Target Raised to $25 by H - GuruFocus
HC Wainwright Forecasts Strong Price Appreciation for Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat
ORIC Pharmaceuticals (ORIC) Analyst Rating Reaffirmed by Wedbush - GuruFocus
Oric Pharmaceuticals' (ORIC) "Outperform" Rating Reiterated at Wedbush - MarketBeat
Oric Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):